Alessia Marrazzo

Partner

Alessia Marrazzo is a Partner at Lear, with extensive experience in litigation, particularly in follow-on damages actions and international arbitration. She also advises clients in proceedings before the Italian Competition Authority, covering a wide range of cases, including cartels, abuses of dominance, and merger investigations.

By combining her background in competition economics and causal inference techniques, Alessia has worked on several support study for DG COMP and National Competition Authorities, aimed at providing an ex-post evaluation of competition policy (mainly related to the State aid framework and merger regulation).

Alessia has worked in a variety of sectors, ranging from telecoms, energy, transport, media, jet fuel, prestressed concrete and plastic packaging. She has advised clients in both the public and private sectors, including Enel, Ferrovie dello Stato Italiane, Free to X, Mediaset, Smurfit Kappa, the Competition and Markets Authority, the Commission for Competition and Consumers in Singapore, the European Commission, the Netherlands Authority for Consumers and Markets and the World Bank.

Alessia teaches a post-graduate course of Economics of Competition at the University of Bologna and she is part of the Executive Committee of the Italian Antitrust Association.

Alessia has earned a PhD in Economics at the University of Bologna, deepening her knowledge in industrial organization and applied economics. She specialized in competition, regulation and applied econometrics with a Master at the Barcelona Graduate School of Economics. Previously, she earned a BSc in Economics and a MSc in Economics and Finance from the University “Federico II” of Naples, building a strong foundation in microeconomics.

LATEST ENGAGEMENTS

• Damages quantification for follow-on actions in the trucks sector
  
• Assistance to merging parties in the Sammontana/Forno d’Asolo merger proceedings before the Italian Competition Authority
  
• Support study for DG Comp on the relevance of killer acquisitions in the pharmaceutical sector